MetLife Investment Management’s AtriCure ATRC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $845K | Buy |
30,199
+3,482
| +13% | +$98K | ﹤0.01% | 1609 |
|
|
2026
Q1 | $762K | Sell |
26,717
-237
| -0.9% | -$8.09K | ﹤0.01% | 1543 |
|
|
2025
Q4 | $1.07M | Sell |
26,954
-1,342
| -5% | -$49.2K | 0.01% | 1392 |
|
|
2025
Q3 | $997K | Hold |
28,296
| – | – | ﹤0.01% | 1449 |
|
|
2025
Q2 | $927K | Hold |
28,296
| – | – | 0.01% | 1355 |
|
|
2025
Q1 | $913K | Sell |
28,296
-377
| -1% | -$14K | ﹤0.01% | 1419 |
|
|
2024
Q4 | $876K | Buy |
28,673
+1,260
| +5% | +$40.5K | ﹤0.01% | 1486 |
|
|
2024
Q3 | $769K | Sell |
27,413
-909
| -3% | -$22.4K | ﹤0.01% | 1548 |
|
|
2024
Q2 | $645K | Buy |
28,322
+3,791
| +15% | +$87.5K | ﹤0.01% | 1583 |
|
|
2024
Q1 | $746K | Hold |
24,531
| – | – | 0.01% | 1461 |
|
|
2023
Q4 | $876K | Hold |
24,531
| – | – | 0.01% | 1372 |
|
|
2023
Q3 | $1.07M | Hold |
24,531
| – | – | 0.01% | 1191 |
|
|
2023
Q2 | $1.21M | Buy |
24,531
+390
| +2% | +$18K | 0.01% | 1159 |
|
|
2023
Q1 | $1M | Hold |
24,141
| – | – | 0.01% | 1223 |
|
|
2022
Q4 | $1.07M | Hold |
24,141
| – | – | 0.01% | 1183 |
|
|
2022
Q3 | $944K | Hold |
24,141
| – | – | 0.01% | 1221 |
|
|
2022
Q2 | $986K | Hold |
24,141
| – | – | 0.01% | 1211 |
|
|
2022
Q1 | $1.59M | Buy |
24,141
+8,549
| +55% | +$554K | 0.01% | 1085 |
|
|
2021
Q4 | $1.08M | Hold |
15,592
| – | – | 0.01% | 1097 |
|
|
2021
Q3 | $1.08M | Sell |
15,592
-1,119
| -7% | -$86.1K | 0.01% | 1083 |
|
|
2021
Q2 | $1.33M | Hold |
16,711
| – | – | 0.01% | 1033 |
|
|
2021
Q1 | $1.09M | Sell |
16,711
-1,933
| -10% | -$119K | 0.01% | 1112 |
|
|
2020
Q4 | $1.04M | Hold |
18,644
| – | – | 0.01% | 1113 |
|
|
2020
Q3 | $744K | Buy |
18,644
+1,250
| +7% | +$53K | 0.01% | 1175 |
|
|
2020
Q2 | $782K | Buy |
17,394
+1,124
| +7% | +$48.9K | 0.01% | 1136 |
|
|
2020
Q1 | $547K | Hold |
16,270
| – | – | 0.01% | 1171 |
|
|
2019
Q4 | $529K | Hold |
16,270
| – | – | 0.01% | 1436 |
|
|
2019
Q3 | $406K | Hold |
16,270
| – | – | ﹤0.01% | 1534 |
|
|
2019
Q2 | $485K | Sell |
16,270
-32,540
| -67% | -$950K | 0.01% | 1493 |
|
|
2019
Q1 | $1.31M | Buy |
48,810
+32,540
| +200% | +$988K | ﹤0.01% | 1506 |
|
|
2018
Q4 | $498K | Hold |
16,270
| – | – | 0.01% | 1372 |
|
|
2018
Q3 | $570K | Hold |
16,270
| – | – | 0.01% | 1452 |
|
|
2018
Q2 | $440K | Hold |
16,270
| – | – | 0.01% | 1478 |
|
|
2018
Q1 | $334K | Hold |
16,270
| – | – | ﹤0.01% | 1625 |
|
|
2017
Q4 | $297K | Buy |
+16,270
| New | +$322K | ﹤0.01% | 1715 |
|
Other funds holding ATRC
HRCM
NAMI
MetLife Investment Management's ATRC Position: Q2 2026 in Review
MetLife Investment Management increased its AtriCure (ATRC) stake by 13% in Q2 2026, buying an estimated $98K and bringing the position to 30,199 shares worth $845K. The position accounts for ﹤0.01% of the portfolio, ranked #1609.
MetLife Investment Management first reported a position in ATRC in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.59M in Q1 2022. 251 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.
- MetLife Investment Management held 30,199 shares of AtriCure worth $845K as of Q2 2026.
- MetLife Investment Management bought 3,482 AtriCure shares in Q2 2026, an estimated $98K.
- AtriCure made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1609 holding.
- MetLife Investment Management first reported a position in AtriCure in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's AtriCure position peaked at $1.59M in Q1 2022.
- 251 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.